D
Ascendis Pharma A/S
ASND
$167.11
-$1.73-1.03%
D
Sell
11/10/2023Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D- from E+ on 11/10/2023 due to an increase in the valuation index, growth index and total return index. Operating cash flow increased 18.56% from -$166.68M to -$135.75M, EBIT increased 4.57% from -$153.3M to -$146.29M, and total revenue increased 1.35% from $51.59M to $52.28M.
Ascendis Pharma A/S (ASND) was upgraded to D- from E+ on 11/10/2023 due to an increase in the valuation index, growth index and total return index. Operating cash flow increased 18.56% from -$166.68M to -$135.75M, EBIT increased 4.57% from -$153.3M to -$146.29M, and total revenue increased 1.35% from $51.59M to $52.28M.
E
Sell
4/3/2023Downgrade
Ascendis Pharma A/S (ASND) was downgraded to E+ from D- on 4/3/2023 due to a decline in the volatility index.
Ascendis Pharma A/S (ASND) was downgraded to E+ from D- on 4/3/2023 due to a decline in the volatility index.
D
Sell
3/14/2023Downgrade
Ascendis Pharma A/S (ASND) was downgraded to D- from D on 03/14/2023.
Ascendis Pharma A/S (ASND) was downgraded to D- from D on 03/14/2023.
D
Sell
2/21/2023Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D from D- on 2/21/2023 due to an increase in the volatility index.
Ascendis Pharma A/S (ASND) was upgraded to D from D- on 2/21/2023 due to an increase in the volatility index.
D
Sell
2/8/2023Downgrade
Ascendis Pharma A/S (ASND) was downgraded to D- from D on 2/8/2023 due to a decline in the growth index, solvency index and valuation index. Earnings per share declined from -$1.552 to -$3.0492, debt to equity increased from 0.69 to 1.02, and the quick ratio declined from 8.48 to 6.59.
Ascendis Pharma A/S (ASND) was downgraded to D- from D on 2/8/2023 due to a decline in the growth index, solvency index and valuation index. Earnings per share declined from -$1.552 to -$3.0492, debt to equity increased from 0.69 to 1.02, and the quick ratio declined from 8.48 to 6.59.
D
Sell
8/12/2022Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D from D- on 8/12/2022 due to an increase in the growth index and volatility index. Earnings per share increased from -$2.481 to -$1.5522, and operating cash flow increased 9.65% from -$146.66M to -$132.5M.
Ascendis Pharma A/S (ASND) was upgraded to D from D- on 8/12/2022 due to an increase in the growth index and volatility index. Earnings per share increased from -$2.481 to -$1.5522, and operating cash flow increased 9.65% from -$146.66M to -$132.5M.
D
Sell
5/31/2022Downgrade
Ascendis Pharma A/S (ASND) was downgraded to D- from D on 5/31/2022 due to a decline in the total return index, volatility index and valuation index.
Ascendis Pharma A/S (ASND) was downgraded to D- from D on 5/31/2022 due to a decline in the total return index, volatility index and valuation index.
D
Sell
5/16/2022Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Ascendis Pharma A/S (ASND) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Ascendis Pharma A/S (ASND) was downgraded to E+ from D on 5/13/2022 due to a large decline in the solvency index, growth index and total return index. Debt to equity increased from 0.01 to 0.56, earnings per share declined from -$2.135 to -$2.481, and EBIT declined 11.47% from -$128.79M to -$143.56M.
Ascendis Pharma A/S (ASND) was downgraded to E+ from D on 5/13/2022 due to a large decline in the solvency index, growth index and total return index. Debt to equity increased from 0.01 to 0.56, earnings per share declined from -$2.135 to -$2.481, and EBIT declined 11.47% from -$128.79M to -$143.56M.
D
Sell
5/4/2022Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
Ascendis Pharma A/S (ASND) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
E
Sell
5/1/2022Downgrade
Ascendis Pharma A/S (ASND) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
Ascendis Pharma A/S (ASND) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
Ascendis Pharma A/S (ASND) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
Ascendis Pharma A/S (ASND) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the total return index, volatility index and valuation index.
Ascendis Pharma A/S (ASND) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the total return index, volatility index and valuation index.
D
Sell
11/23/2021Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index and valuation index.
Ascendis Pharma A/S (ASND) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index and valuation index.
D
Sell
11/8/2021Downgrade
Ascendis Pharma A/S (ASND) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the volatility index, solvency index and valuation index. The quick ratio declined from 9.21 to 8.
Ascendis Pharma A/S (ASND) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the volatility index, solvency index and valuation index. The quick ratio declined from 9.21 to 8.
D
Sell
3/24/2021Downgrade
Ascendis Pharma A/S (ASND) was downgraded to D from D+ on 3/24/2021 due to a significant decline in the total return index, growth index and solvency index. Total revenue declined 80.22% from $3.22M to $637.7, operating cash flow declined 59.24% from -$67.62M to -$107.68M, and EBIT declined 23.67% from -$92.19M to -$114.01M.
Ascendis Pharma A/S (ASND) was downgraded to D from D+ on 3/24/2021 due to a significant decline in the total return index, growth index and solvency index. Total revenue declined 80.22% from $3.22M to $637.7, operating cash flow declined 59.24% from -$67.62M to -$107.68M, and EBIT declined 23.67% from -$92.19M to -$114.01M.
D
Sell
5/1/2020Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D+ from D on 5/1/2020 due to a noticeable increase in the total return index and volatility index.
Ascendis Pharma A/S (ASND) was upgraded to D+ from D on 5/1/2020 due to a noticeable increase in the total return index and volatility index.
D
Sell
4/6/2020Downgrade
Ascendis Pharma A/S (ASND) was downgraded to D from D+ on 4/6/2020 due to a decline in the growth index, efficiency index and volatility index. Net income declined 218.61% from -$27.93M to -$88.98M, earnings per share declined from -$0.5868 to -$1.8605, and EBIT declined 19.53% from -$60.07M to -$71.8M.
Ascendis Pharma A/S (ASND) was downgraded to D from D+ on 4/6/2020 due to a decline in the growth index, efficiency index and volatility index. Net income declined 218.61% from -$27.93M to -$88.98M, earnings per share declined from -$0.5868 to -$1.8605, and EBIT declined 19.53% from -$60.07M to -$71.8M.
D
Sell
11/20/2019Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D+ from D on 11/20/2019 due to an increase in the growth index and efficiency index. Earnings per share increased from -$1.4026 to -$0.5868, and net income increased 57.8% from -$66.19M to -$27.93M.
Ascendis Pharma A/S (ASND) was upgraded to D+ from D on 11/20/2019 due to an increase in the growth index and efficiency index. Earnings per share increased from -$1.4026 to -$0.5868, and net income increased 57.8% from -$66.19M to -$27.93M.
D
Sell
10/30/2019Downgrade
Ascendis Pharma A/S (ASND) was downgraded to D from D+ on 10/30/2019 due to a significant decline in the total return index, efficiency index and solvency index. The quick ratio declined from 21.97 to 11.43, net income declined 8.63% from -$60.93M to -$66.19M, and total capital declined 1.76% from $823.96M to $809.49M.
Ascendis Pharma A/S (ASND) was downgraded to D from D+ on 10/30/2019 due to a significant decline in the total return index, efficiency index and solvency index. The quick ratio declined from 21.97 to 11.43, net income declined 8.63% from -$60.93M to -$66.19M, and total capital declined 1.76% from $823.96M to $809.49M.
D
Sell
5/31/2019Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D+ from D on 5/31/2019 due to a substantial increase in the total return index, growth index and volatility index.
Ascendis Pharma A/S (ASND) was upgraded to D+ from D on 5/31/2019 due to a substantial increase in the total return index, growth index and volatility index.
D
Sell
3/24/2017Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D from D- on 3/24/2017 due to a major increase in the total return index, solvency index and efficiency index. Total capital increased 122.93% from $83.63M to $186.44M, the quick ratio increased from 6.32 to 13.52, and net income increased 13.11% from -$20.43M to -$17.75M.
Ascendis Pharma A/S (ASND) was upgraded to D from D- on 3/24/2017 due to a major increase in the total return index, solvency index and efficiency index. Total capital increased 122.93% from $83.63M to $186.44M, the quick ratio increased from 6.32 to 13.52, and net income increased 13.11% from -$20.43M to -$17.75M.
D
Sell
12/2/2016Downgrade
Ascendis Pharma A/S (ASND) was downgraded to D- from D on 12/2/2016 due to a decline in the growth index, efficiency index and solvency index. Net income declined 35.79% from -$15.01M to -$20.38M, earnings per share declined from -$0.5987 to -$0.8087, and operating cash flow declined 22.54% from -$14.44M to -$17.69M.
Ascendis Pharma A/S (ASND) was downgraded to D- from D on 12/2/2016 due to a decline in the growth index, efficiency index and solvency index. Net income declined 35.79% from -$15.01M to -$20.38M, earnings per share declined from -$0.5987 to -$0.8087, and operating cash flow declined 22.54% from -$14.44M to -$17.69M.
D
Sell
10/3/2016Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D from D- on 10/3/2016 due to an increase in the volatility index and total return index.
Ascendis Pharma A/S (ASND) was upgraded to D from D- on 10/3/2016 due to an increase in the volatility index and total return index.
D
Sell
5/20/2016Downgrade
Ascendis Pharma A/S (ASND) was downgraded to D- from D on 5/20/2016 due to a noticeable decline in the volatility index, solvency index and growth index. Earnings per share declined from -$0.5255 to -$0.9045, operating cash flow declined 50.04% from -$10.94M to -$16.42M, and total revenue declined 35.95% from $2.17M to $1.39M.
Ascendis Pharma A/S (ASND) was downgraded to D- from D on 5/20/2016 due to a noticeable decline in the volatility index, solvency index and growth index. Earnings per share declined from -$0.5255 to -$0.9045, operating cash flow declined 50.04% from -$10.94M to -$16.42M, and total revenue declined 35.95% from $2.17M to $1.39M.
D
Sell
2/1/2016Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D from D- on 2/1/2016 due to an increase in the growth index and solvency index. The quick ratio increased from 11.46 to 13.82, and total revenue increased 9.46% from $2.15M to $2.35M.
Ascendis Pharma A/S (ASND) was upgraded to D from D- on 2/1/2016 due to an increase in the growth index and solvency index. The quick ratio increased from 11.46 to 13.82, and total revenue increased 9.46% from $2.15M to $2.35M.
D
Sell
10/1/2015Upgraded
Ascendis Pharma A/S (ASND) was upgraded to D- from E+ on 10/1/2015 due to a large increase in the total return index and volatility index.
Ascendis Pharma A/S (ASND) was upgraded to D- from E+ on 10/1/2015 due to a large increase in the total return index and volatility index.
E
Sell
7/1/2015Upgraded
Ascendis Pharma A/S (ASND) was upgraded to E+ from E on 7/1/2015 due to a major increase in the solvency index, growth index and total return index. The quick ratio increased from 4.09 to 12.85.
Ascendis Pharma A/S (ASND) was upgraded to E+ from E on 7/1/2015 due to a major increase in the solvency index, growth index and total return index. The quick ratio increased from 4.09 to 12.85.
E
Sell
4/23/2015None
Ascendis Pharma A/S (ASND) was downgraded to E from U on 04/23/2015.
Ascendis Pharma A/S (ASND) was downgraded to E from U on 04/23/2015.
NASDAQ
03/18/2025 11:01AM Eastern
Quotes delayed
